We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+42.91%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$161M
AUM Growth
+$37.8M
Cap. Flow
+$27M
Cap. Flow %
16.75%
Top 10 Hldgs %
99.16%
Holding
12
New
1
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$19.5M
2
TRVI icon
Trevi Therapeutics
TRVI
+$7.13M
3
ZBIO
Zenas BioPharma
ZBIO
+$413K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCS icon
1
Oculis Holding
OCS
$708M
$44.7M 27.68%
2,300,774
– –
PCVX icon
2
Vaxcyte
PCVX
$8.81B
$42.4M 26.3%
1,305,125
+594,391
+84% +$19.5M
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.3B
$29.7M 18.43%
2,120,508
– –
INZY
4
DELISTED
Inozyme Pharma
INZY
$18M 11.14%
4,494,851
– –
ZBIO
5
Zenas BioPharma
ZBIO
$2.05B
$7.55M 4.68%
779,045
+42,400
+6% +$413K
TRVI icon
6
Trevi Therapeutics
TRVI
$2.54B
$6.27M 3.89%
+1,146,110
New +$7.13M
VIGL
7
DELISTED
Vigil Neuroscience
VIGL
$4.46M 2.76%
560,595
– –
RXRX icon
8
Recursion Pharmaceuticals
RXRX
$1.8B
$3.01M 1.87%
595,518
– –
BIOA
9
BioAge Labs
BIOA
$490M
$2.7M 1.67%
653,374
– –
IOBT
10
DELISTED
IO Biotech
IOBT
$1.2M 0.74%
864,197
– –
RLYB icon
11
Rallybio
RLYB
$87M
$813K 0.5%
300,581
– –
BOLT icon
12
Bolt Biotherapeutics
BOLT
$7.65M
$546K 0.34%
94,573
– –

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q2 2025 Portfolio in Review

As of Q2 2025, Pivotal bioVenture Partners Investment Advisor held 12 positions worth $161M, up 31% from $124M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Pivotal bioVenture Partners Investment Advisor deployed $27M of net new capital in Q2 2025, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Trevi Therapeutics: 1,146,110 shares worth $6.27M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pivotal bioVenture Partners Investment Advisor's largest Q2 2025 buy was Trevi Therapeutics: 1,146,110 shares worth $6.27M.
  • Pivotal bioVenture Partners Investment Advisor added most to Vaxcyte in Q2 2025, an estimated $19.5M increase.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 99% of its $161M portfolio in Q2 2025.
  • Pivotal bioVenture Partners Investment Advisor opened 1 new position and closed 0 in Q2 2025.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 31% quarter-over-quarter to $161M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2025, filed 13 Aug 2025.